Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. is dated April 6, 2021, covering the month of April 2021. The filing serves as an amendment to Exhibit 15.1 of the Company's Annual Report on Form 20-F for the year ended December 31, 2020.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural amendment regarding auditor consent and does not contain new financial data or results.
Material Changes
There are no material changes to previously reported financial results or other disclosures. The filing explicitly states that the revised exhibit supersedes the original only to correct an inadvertent omission of a reference to the Company's Registration Statement on Form F-3 (File No. 333-248740).
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. Its sole purpose is to update the consent of the independent registered public accounting firm, Deloitte Accountants B.V., to ensure it properly references the Company's Form F-3 registration statements.
Investor Verification Checklist
- Verify that the original Form 20-F filed on March 24, 2021, remains the authoritative source for 2020 financial results.
- Confirm that the auditor's consent now correctly references Registration Statement File No. 333-248740.
- Note that this filing incorporates by reference into Registration Statements File No. 333-228251 and File No. 333-248740.